[1] Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O’Meara MJ, Rezelj VV, Guo JZ, Swaney DL, Tummino TA, Huettenhain R, Kaake RM, Richards AL, Tutuncuoglu B, Foussard H, Batra J, Haas K, Modak M, Kim M, Haas P, Polacco BJ, Braberg H, Fabius JM, Eckhardt M, Soucheray M, Bennett MJ, Cakir M, McGregor MJ, Li Q, Meyer B, Roesch F, Vallet T, Mac Kain A, Miorin L, Moreno E, Naing ZZC, Zhou Y, Peng S, Shi Y, Zhang Z, Shen W, Kirby IT, Melnyk JE, Chorba JS, Lou K, Dai SA, Barrio-Hernandez I, Memon D, Hernandez-Armenta C, Lyu J, Mathy CJP, Perica T, Pilla KB, Ganesan SJ, Saltzberg DJ, Rakesh R, Liu X, Rosenthal SB, Calviello L, Venkataramanan S, Liboy-Lugo J, Lin Y, Huang XP, Liu Y, Wankowicz SA, Bohn M, Safari M, Ugur FS, Koh C, Savar NS, Tran QD, Shengjuler D, Fletcher SJ, O’Neal MC, Cai Y, Chang JCJ, Broadhurst DJ, Klippsten S, Sharp PP, Wenzell NA, Kuzuoglu D, Wang HY, Trenker R, Young JM, Cavero DA, Hiatt J, Roth TL, Rathore U, Subramanian A, Noack J, Hubert M, Stroud RM, Frankel AD, Rosenberg OS, Verba KA, Agard DA, Ott M, Emerman M, Jura N, von Zastrow M, Verdin E, Ashworth A, Schwartz O, d’Enfert C, Mukherjee S, Jacobson M, Malik HS, Fujimori DG, Ideker T, Craik CS, Floor SN, Fraser JS, Gross JD, Sali A, Roth BL, Ruggero D, Taunton J, Kortemme T, Beltrao P, Vignuzzi M, García-Sastre A, Shokat KM, Shoichet BK, Krogan NJ. A SARS-CoV–2 protein interaction map reveals targets for drug repurposing. Nature. 2020 Apr 30. doi: 10.1038/s41586–020–2286–9.
[6] Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, Sabedot TS, Malta TM, Pagnotta SM, Castiglioni I, Ceccarelli M, Bontempi G, Noushmehr H. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data.Nucleic Acids Res. 2016 May 5;44(8):e71. doi: 10.1093/nar/gkv1507
[7] Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012 May;16(5):284–7. doi: 10.1089/omi.2011.0118
[8] Cava C, Bertoli G, Castiglioni I. In silico identification of drug target pathways in breast cancer subtypes using pathway cross-talk inhibition. J Transl Med. 2018 Jun 5;16(1):154. doi: 10.1186/s12967–018–1535–2
[9] Cava C, Colaprico A, Bertoli G, Graudenzi A, Silva TC, Olsen C, Noushmehr H, Bontempi G, Mauri G, Castiglioni I. SpidermiR: An R/Bioconductor Package for Integrative Analysis with miRNA Data. Int J Mol Sci. 2017 Jan 27;18(2). pii:E274. doi: 10.3390/ijms18020274
[10] Wagner AH, Coffman AC, Ainscough BJ, Spies NC, Skidmore ZL, Campbell KM, Krysiak K, Pan D, McMichael JF, Eldred JM, Walker JR, Wilson RK, Mardis ER, Griffith M, Griffith OL. DGIdb 2.0: mining clinically relevant drug-gene interactions. Nucleic Acids Res. 2016 Jan 4;44(D1):D1036–44. doi:10.1093/nar/gkv1165
[11] Clauset, A., Newman, M. E., & Moore, C. (2004). Finding community structure in very large networks. Physical review. E, Statistical, nonlinear, and soft matter physics, 70 6 Pt 2, 066111
[12] Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, Li Q, Shoemaker BA, Thiessen PA, Yu B, Zaslavsky L, Zhang J, Bolton EE. PubChem 2019 update: improved access to chemical data. Nucleic Acids Res. 2019 Jan 8;47(D1):D1102-D1109. doi: 10.1093/nar/gky1033
[13] BIOvIA, D. S. (2015). Discovery studio modeling environment. San Diego, Dassault Systemes, Release, 4
[14] Goodsell DS, Olson AJ. Automated docking of substrates to proteins by simulated annealing. Proteins. 1990;8(3):195–202
[15] Brown EE, Kumar S, Rajji TK, Pollock BG, Mulsant BH. Anticipating and Mitigating the Impact of the COVID–19 Pandemic on Alzheimer’s Disease and Related Dementias [published online ahead of print, 2020 Apr 18]. Am J Geriatr Psychiatry. 2020;S1064–7481(20)30294–3. doi:10.1016/j.jagp.2020.04.010
[16] Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, Zhang X, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020 May 1;130(5):2620–2629. doi: 10.1172/JCI137244
[17] Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG. Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener. 2009 Nov 16;4:47. doi: 10.1186/1750–1326–4–47
[18] Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci. 2005 Sep 7;25(36):8240–9
[19] Fung SY, Yuen KS, Ye ZW, Chan CP, Jin DY. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes Infect. 2020 Mar 14;9(1):558–570. doi:10.1080/22221751.2020.
[20] Li H, Chen C, Hu F, Wang J, Zhao Q, Gale RP, Liang Y. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV–2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. Leukemia. 2020 May 5. doi: 10.1038/s41375–020–0848–3. [Epub ahead of print]
[21] Gao QY, Chen YX, Fang JY. 2019 Novel coronavirus infection and gastrointestinal tract. J Dig Dis. 2020;21(3):125‐126. doi:10.1111/1751–2980.12851
[22] Budden KF, Gellatly SL, Wood DL, Cooper MA, Morrison M, Hugenholtz P, Hansbro PM. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol. 2017 Jan;15(1):55–63. doi: 10.1038/nrmicro.2016.142
[23] He Y, Wen Q, Yao F, Xu D, Huang Y, Wang J. Gut-lung axis: The microbial contributions and clinical implications. Crit Rev Microbiol. 2017 Feb;43(1):81–95. doi: 10.1080/1040841X.2016.1176988
[24] Prins GH, Olinga P. Potential implications of COVID–19 in non-alcoholic fattyliver disease. Liver Int. 2020 Apr 19. doi: 10.1111/liv.14484. [Epub ahead of print]
[25] Pirola CJ, Sookoian S. SARS-CoV–2 virus and liver expression of host receptors: Putative mechanisms of liver involvement in COVID–19. Liver Int. 2020 Apr 30. doi: 10.1111/liv.14500. [Epub ahead of print]
[26] Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, Lau G. Non-alcoholic fatty liver diseases in patients with COVID–19: A retrospective study. J Hepatol. 2020 Apr 8. pii: S0168–8278(20)30206–3. doi: 10.1016/j.jhep.2020.03.044. [Epub ahead of print]
[27] Lehrer S. Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review). World Acad Sci J. 2020 May;2(3). pii: 1. doi: 10.3892/wasj.2020.42
[28] Maiese K. The mechanistic target of rapamycin (mTOR): Novel Considerations as an Antiviral Treatment and Possibilities for COVID–19. Curr Neurovasc Res. 2020 Apr 25. doi: 10.2174/1567202617666200425205122
[29] Bowman LJ, Brueckner AJ, Doligalski CT. The Role of mTOR Inhibitors in the Management of Viral Infections: A Review of Current Literature. Transplantation. 2018 Feb;102(2S Suppl 1):S50-S59. doi: 10.1097/TP.0000000000001777
[30] Jelski W, Strumnik A, Orywal K, Lapinski TW, Swiderska M, Szmitkowski M. Activity of alcohol dehydrogenase isoenzymes and aldehyde dehydrogenase in sera of patients with hepatitis C. Arch Med Sci. 2018 Mar;14(2):281–287. doi: 10.5114/aoms.2016.60406
[31] Al Saleh AS, Sher T, Gertz MA. Multiple Myeloma in the Time of COVID–19. Acta Haematol. 2020 Apr 17:1–7. doi: 10.1159/000507690.
[32] Schneider M, Ackermann K, Stuart M, Wex C, Protzer U, Schätzl HM, Gilch S. Severe acute respiratory syndrome coronavirus replication is severely impaired by MG132 due to proteasome-independent inhibition of M-calpain. J Virol. 2012 Sep;86(18):10112–22. doi: 10.1128/JVI.01001–12
[33] Raaben M, Posthuma CC, Verheije MH, te Lintelo EG, Kikkert M, Drijfhout JW, Snijder EJ, Rottier PJ, de Haan CA. The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle. J Virol. 2010 Aug;84(15):7869–79. doi: 10.1128/JVI.00485–10
[34] Pal R, Bhadada SK. Should anti-diabetic medications be reconsidered amid COVID–19 pandemic? Diabetes Res Clin Pract. 2020 Apr 10;163:108146. doi:10.1016/j.diabres.2020.108146.
[35] Nakhleh A, Shehadeh N. Interactions between antihyperglycemic drugs and the renin-angiotensin system: Putative roles in COVID–19. A mini-review. Diabetes Metab Syndr. 2020 May 5;14(4):509–512. doi: 10.1016/j.dsx.2020.04.040.
[36] Nedu ME, Tertis M, Cristea C, Georgescu AV. Comparative Study Regarding the Properties of Methylene Blue and Proflavine and Their Optimal Concentrations for In Vitro and In Vivo Applications. Diagnostics (Basel). 2020 Apr 15;10(4). pii: E223. doi: 10.3390/diagnostics10040223
[37] Wang Y, Ren K, Liao X, Luo G, Kumthip K, Leetrakool N, Li S, Chen L, Yang C, Chen Y. Inactivation of Zika virus in plasma and derivatives by four different methods. J Med Virol. 2019 Dec;91(12):2059–2065. doi: 10.1002/jmv.25538
[38] Quintana VM, Selisko B, Brunetti JE, Eydoux C, Guillemot JC, Canard B, Damonte EB, Julander JG, Castilla V. Antiviral activity of the natural alkaloid anisomycin against dengue and Zika viruses. Antiviral Res. 2020 Apr;176:104749. doi: 10.1016/j.antiviral.2020.104749
[39] Ramabhadran TV, Thach RE. Specificity of protein synthesis inhibitors in the inhibition of encephalomyocarditis virus replication. J Virol. 1980 Apr;34(1):293–6
[40] Hwang YC, Chu JJ, Yang PL, Chen W, Yates MV. Rapid identification of inhibitors that interfere with poliovirus replication using a cell-based assay. Antivir Res. 2008;77(3):232–236. doi: 10.1016/j.antiviral.2007.12.009
[41] Chang CC, Ou YC, Raung SL, Chen CJ. Antiviral effect of dehydroepiandrosterone on Japanese encephalitis virus infection. J Gen Virol. 2005 Sep;86(Pt9):2513–2523. doi: 10.1099/vir.0.81123–0
[42] Murray JL, McDonald NJ, Sheng J, Shaw MW, Hodge TW, Rubin DH, O’Brien WA, Smee DF. Inhibition of influenza A virus replication by antagonism of a PI3K-AKT-mTOR pathway member identified by gene-trap insertional mutagenesis. Antivir Chem Chemother. 2012 May 14;22(5):205–15. doi: 10.3851/IMP2080
[43] Dyall J, Gross R, Kindrachuk J, Johnson RF, Olinger GG Jr, Hensley LE, Frieman MB, Jahrling PB. Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies. Drugs. 2017 Dec;77(18):1935–1966. doi: 10.1007/s40265–017–0830–1
[44] Kindrachuk J, Ork B, Hart BJ, Mazur S, Holbrook MR, Frieman MB, Traynor D, Johnson RF, Dyall J, Kuhn JH, Olinger GG, Hensley LE, Jahrling PB. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob Agents Chemother. 2015 Feb;59(2):1088–99. doi: 10.1128/AAC.03659–14
[45] Northrop RL. Effect of puromycin and actinomycin D on a persistent mumps virus infection in vitro. J Virol. 1969 Aug;4(2):133–40